CliffBio
biologic

Vaxchora

Cholera Vaccine, Live, Oral

Loss of exclusivityJune 2028projected — 12-year biologic exclusivity estimate
CompanyBavarian Nordic A/S

Drug detail

Brand nameVaxchora
Active ingredientCholera Vaccine, Live, Oral
Strength100ML
Dosage formSuspension
RouteOral
ModalityBiologic
FDA approvalJune 2016
Marketing statusRx

More from Bavarian Nordic A/S

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Vaxchora patent cliff — loss of exclusivity June 2028 | CliffBio